Uncover our world leading platform

On the pursuit to develop the most stable and potent targeted Treg cell therapies

Manufacturing Process

We are a clinical stage company at the forefront of the Treg cell therapy field. With deep GMP experience and over several hundred scale runs to date, we pride ourselves on the continued delivery of the highest manufacturing standards. Our experience at therapeutic scale has driven significant improvements, making our manufacturing process highly efficient, stable, and effective for delivering transformative cell products to patients.

Posters

Explore our cutting-edge posters

QEL-001 LIBERATE Study Expansion Cohort CAR-Treg engraftment and expansion following rATG conditioning in liver transplantation

EASL, May 2025

Characterization of engineered CAR-Treg cells to induce immune tolerance in liver transplanted patients

International Society for Cell & Gene Therapy (ISCT), May 2025

CAR-Treg cell therapy to induce tolerance in liver transplantation - Initial insights from the LIBERATE Clinical Trial

Immune Cell Therapies: Advances in Cancer and Autoimmune Disease (Keystone), Mar 2025

The safety and tolerability of QEL-001, an autologous Chimeric Antigen Receptor T regulatory (CAR-Treg) cell therapy, in liver transplantation – A safety cohort in the LIBERATE study

American Association for the Study of Liver Diseases (AASLD), Nov 2024

Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditions

European Society of Gene and Cell Therapy (ESGCT), Oct 2024

Engineering Multi-modular Tregs with CARs, a Foxp3 Phenotype Lock and Synthetic Cytokine Receptors enhances their therapeutic potential for a broad range of immune conditions

American Society of Gene & Cell Therapy (ASGCT), May 2024